Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16379700 | 1.00 | KDM4E (0.37) | KDM4ERECQLCA2HTR1DHTR1B | |
| SCHEMBL16806579 | 1.00 | KDM4E (0.37) | KDM4ERECQLCA2HTR1DHTR1B | |
| SCHEMBL27333126 | 1.00 | KDM4E (0.37) | KDM4ERECQLCA2HTR1DHTR1B | |
| SCHEMBL39815 | 1.00 | KDM4E (0.37) | KDM4ERECQLCA2HTR1DHTR1B | |
| SCHEMBL6935868 | 1.00 | — | — | |
| SCHEMBL19202513 | 1.00 | KDM4E (0.37) | KDM4ERECQLCA2HTR1DHTR1B | |
| SCHEMBL15984875 | 1.00 | KDM4E (0.37) | KDM4ERECQLCA2HTR1DHTR1B | |
| SCHEMBL17243850 | 1.00 | KDM4E (0.37) | KDM4ERECQLCA2HTR1DHTR1B | |
| SCHEMBL21876827 | 1.00 | KDM4E (0.37) | KDM4ERECQLCA2HTR1DHTR1B | |
| Bromide SCHEMBL23217987 | 0.97 | KDM4E (0.36) | KDM4ERECQLCA2HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025105486-A1 | ANTIBODY-PHOTOSENSITIVE SUBSTANCE CONJUGATE | 第一三共株式会社 | 2025-05-22 | — | — | WO | disclosed |
| EP-4436972-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | RMW Cho Group Limited (HK) | 2024-10-02 | — | — | EP | disclosed |
| EP-4395549-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | Oerth Bio LLC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20230365577-A1 | Photodynamic Therapy and Diagnosis | RMW CHO GROUP LIMITED (HK) | 2023-11-16 | — | — | US | disclosed |
| US-20230332145-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2023094679-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | RMW CHO GROUP LIMITED (CN) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023094677-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | RMW CHO GROUP LIMITED (CN) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023081141-A1 | THYMIDYLATE SYNTHASE INHIBITORS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230104936-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2023034411-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | OERTH BIO LLC (US) | 2023-03-09 | — | — | WO | disclosed |
| US-9878047-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170247403-A1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2017-08-31 | — | — | US | disclosed |
| US-20170247403-A1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2017-08-31 | — | — | US | disclosed |
| WO-2017030814-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | Arvinas, Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017011371-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS, INC (US) | 2017-01-19 | — | — | WO | disclosed |
| US-9061069-B2 | Use of constrained peptide mimic oligomers as vectorization agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-06-23 | — | — | US | disclosed |
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20120184480-A1 | USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS | UNIVERSITE DE MONTPELLIER I (FR) | 2012-07-19 | — | — | US | disclosed |
| US-6187955-B1 | A MOISTURIZER FOR SOFTENING SKINS; USEFUL AS COMPONENTS OF COSMETIC FORMULATIONS | KAO CORPORATION (JP) | 2001-02-13 | — | — | US | disclosed |
| US-5723133-A | GUANIDINE WITH ORGANIC ACID FOR SKIN SOFTENING | KAO CORPORATION (JP) | 1998-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | BRDT, BRD2, BRD4 | KDM4E 1492/4885RECQL 1712/4885CA2 3216/4885 |
| US-20120184480-A1 | USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS | DNPEP, IAPP, VIP | KDM4E 4771/4885RECQL 2423/4885CA2 3146/4885 |
| US-20230104936-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | KDM4E 2480/4885RECQL 3040/4885CA2 294/4885 |
| US-20170247403-A1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | ANTXR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBXA2R | KDM4E 3461/4885RECQL 59/4885CA2 1291/4885 |
| US-20230332145-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | EFTUD2, DDX21, SNRPE | KDM4E 4176/4885RECQL 794/4885CA2 4173/4885 |
| US-20230365577-A1 | Photodynamic Therapy and Diagnosis | PPOX, PPIF, ALAD | KDM4E 4532/4885RECQL 1645/4885CA2 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.